论文部分内容阅读
应用重组干扰素α-2b对20例慢性活动性乙型病毒性肝炎患者进行了临床对照研究。治疗组10例采用IntronA5mu,每周3次,皮下注射,疗程12周、其中8例治疗前应用短程皮质激素撤除疗法。对照组10例采用常规护肝药物。在随访1年时,治疗组8例症状消失,ALT持续正常水平,2例各有一次复发,症状再现,ALT升高,85.7％(6/7)HBeAg血清转换为抗HBe,30％(3/10)HBV-DNA阴转。对照组仅5例临床症状消失,ALT持续正常水平或基本正常,5例出现9次复发,症状再现,ALT升高,28.6％(2/7)HBeAg自发阴转,但无1例抗-HBe阳转,10％(1/10)HBV-DNA阴转。重组干扰素治疗期间副反应均可耐受,且呈可逆性改变。结果提示应用短程皮质激意撤除疗法与重组干扰素联合治疗方案是目前治疗我国慢性活动性乙型病毒性肝炎的最有效方法。
The clinical trial of 20 patients with chronic active hepatitis B virus was carried out using recombinant interferon α-2b. Ten patients in the treatment group were treated with IntronA5 mu three times a week for 12 weeks. Eight of them were treated with short-term corticosteroid withdrawal therapy before treatment. Control group, 10 cases of conventional hepatoprotective drugs. At 1 year of follow-up, eight patients in the treatment group disappeared and the ALT level remained normal. There was one recurrence in each of the two cases. The symptoms were elevated and the ALT was elevated. The HBeAg seroconvertions in 85.7% (6/7) / 10) HBV-DNA overcast. In the control group, the clinical symptoms of only 5 patients disappeared. The ALT level remained normal or normal. There were 9 recurrences in 5 patients. The recurrence of symptoms, elevated ALT, spontaneous conversion of HBeAg in 28.6% (2/7), but no anti-HBe Positive rotation, 10% (1/10) HBV-DNA negative. Side effects of recombinant interferon during treatment are tolerable, and were reversibly changed. The results suggest that the application of short-term cortical excision therapy combined with recombinant interferon regimen is the most effective treatment of chronic active hepatitis B in our country.